Volume Spike Investor

IDM Pharma, Inc. (NASDAQ: IDMI) is seeing a volume and major price surge right at the open.  The company received recommendation for approval of Mifamurtide for the treatment of patients with non-metastatic, resectable osteosarcoma in Europe from the Committee for Medicinal Products for Human Use of the European Medicines Agency.  The agency has issued a positive opinion and is recommending grant of a centralized marketing authorization for mifamurtide.  This is known as MEPACT in Europe, for the treatment of patients with non-metastatic, resectable osteosarcoma. This recommendation will be adopted at the next meeting in December, and it looks like final European Commission approval expected within 60 to 90 days thereafter.

At 9;32 AM EST this stock is up over 50% at $2.39 on 43,000 shares.  Its daily average is only about 123,000 shares and this one was briefly up by more than 70% before the open.

Jon C. Ogg
November 18, 2008